<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869501</url>
  </required_header>
  <id_info>
    <org_study_id>TJ004309STM104</org_study_id>
    <nct_id>NCT04869501</nct_id>
  </id_info>
  <brief_title>Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer</brief_title>
  <official_title>Expanded Access Protocol for an Intermediate Size Population-use of TJ004309 in Combination With Atezolizumab (TecentriqÂ®) in Patients With Advanced or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma Co. Ltd.</source>
  <brief_summary>
    <textblock>
      This expanded access protocol was designed to provide TJ004309 in combination with&#xD;
      atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to&#xD;
      continue with treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ004309</intervention_name>
    <description>Antibody to CD73</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Humanized monoclonal antibody to PD-L1</description>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participation in the Tracon sponsored 4309ST101 study and thought to have potential to&#xD;
             derive clinical benefit from continued treatment in the opinion of the parent study&#xD;
             investigator from uninterrupted dosing of TJ004309 in combination with atezolizumab.&#xD;
&#xD;
          2. Willing or able to comply with study treatment and standard of care testing and&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any unresolved ongoing toxicity or clinical event that would make continued treatment&#xD;
             with TJ004309 inappropriate.&#xD;
&#xD;
          2. Current treatment in another clinical study or treatment with other standard of care&#xD;
             therapy.&#xD;
&#xD;
          3. Currently pregnant.&#xD;
&#xD;
          4. Current evidence of any condition (including medical, psychiatric or substance abuse&#xD;
             disorder), therapy, or laboratory abnormality that might interfere with the patient's&#xD;
             participation or is not in the best interest of the patient to participate, in the&#xD;
             opinion of the treating Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

